Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Home Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

/ Publications

Share the Post

About the Author

Related Posts

nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts
Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Read More
Emma Reeve
Read More
Scott Giacobello, CPA
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa
A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer

Comments

Comments are closed.